(Q42781680)
Statements
1 reference
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors (English)
1 reference
Qiong Zhao
1 reference
Jianzhong Shentu
1 reference
Nong Xu
1 reference
Jianya Zhou
1 reference
Guangdie Yang
1 reference
Yinan Yao
1 reference
Fenlai Tan
1 reference
Dongyang Liu
1 reference
Yingxiang Wang
1 reference
Jianying Zhou
1 reference
8 December 2010
1 reference
1 reference
73
1 reference
2
1 reference
195-202
1 reference
Identifiers
1 reference
1 reference